This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_MACROGLOBULINEMIA_EXALLC for full statistics.
Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma
C3_MACROGLOBULINEMIA
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
129 |
4. Check minimum number of eventsNone |
129 |
5. Include endpointsNone |
129 |
6. Filter based on genotype QC (FinnGen only) |
129 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma
based on the number of shared cases.
Similar with more cases:
- Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 129 | 53 | 76 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | 69.66 | 67.09 | 71.46 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 125
- Matched controls
- 1250
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C88.0
ICD-10 Finland
Waldenström macroglobulinaemia
+∞
158.1
116
*
9761/3-C42.0
ICD-O-3
Waldenstrom macroglobulinemia of blood
+∞
98.3
81
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
92.8
81.4
89
32
XW000
NOMESCO Finland
Bone marrow biopsy
60.6
62.5
73
28
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
89.7
35.4
38
6
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
69.9
35.0
39
8
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
36.7
27.6
35
13
9671/3-C42.1
ICD-O-3
Lymphoplasmacytic lymphoma of bone marrow
+∞
27.0
25
*
A04AA01
ATC
ondansetron; systemic, rectal
21.2
26.6
40
27
L03AA02
ATC
filgrastim; parenteral
28.9
23.1
31
14
390
Kela drug reimbursment
Ibrutinib
+∞
20.4
19
*
1512
Kela drug reimbursment
Ibrutinib
+∞
20.4
19
*
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
43.9
18.3
22
6
C83.01
ICD-10 Finland
Lymphoplasmacytic lymphoma
+∞
18.1
17
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
9.7
16.5
35
48
L01AA02
ATC
chlorambucil; oral
91.0
14.9
16
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
22.6
14.8
21
11
L01EL01
ATC
ibrutinib; oral
+∞
13.8
13
*
M04AA01
ATC
allopurinol; systemic
5.0
13.2
50
147
JN4BD
NOMESCO Finland
Extensive body CT
5.9
12.0
36
80
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
10.6
11.9
23
26
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.3
11.9
40
102
L01XE27
ATC
[U] ibrutinib; oral
+∞
11.6
11
*
WW500
NOMESCO Finland
Blood transfusion
11.2
11.3
21
22
C88.9
ICD-10 Finland
Malignant immunoproliferative disease, unspecified
119.5
10.6
11
*
1XC02
NOMESCO Finland
NA
35.9
10.6
13
*
D64.9
ICD-10 Finland
Anaemia, unspecified
4.8
9.6
34
90
L01AA01
ATC
cyclophosphamide; systemic
107.8
9.6
10
*
J05AB11
ATC
valaciclovir; oral
4.9
9.3
32
82
ZX120
NOMESCO Finland
Intravenous
5.3
9.0
28
64
H02AB02
ATC
dexamethasone; systemic
4.9
8.9
30
75
J05AB01
ATC
aciclovir; systemic
3.7
8.5
41
144
L03AA13
ATC
pegfilgrastim; parenteral
12.9
8.3
14
12
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
23.9
8.2
11
5
C85.1
ICD-10 Finland
B-cell lymphoma, unspecified
84.8
7.5
8
*
N08.1*C88.0
ICD-10 Finland
Glomerular disorders in Waldenström's macroglobulinaemia
+∞
7.4
7
*
R50.9
ICD-10 Finland
Fever, unspecified
3.6
7.2
34
116
C90.0
ICD-10 Finland
Multiple myeloma
15.4
6.5
10
7
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
73.4
6.5
7
*
B03XA01
ATC
erythropoietin; parenteral
19.2
6.4
9
5
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
6.3
77
476
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
82
41
53.15
117.11
8.5
2.9
21.88
32.73
mg/l
1.17
67
32
82
41
53.15
117.11
8.6
2.9
118.51
234.21
mg/l
0.32
67
32
64
56
21.70
67.49
13.6
1.4
2.95
3.25
g/l
1.03
45
47
65
60
20.82
66.42
13.4
1.4
3.99
3.69
g/l
0.20
44
46
65
60
20.82
66.42
13.5
1.4
6.98
7.94
g/l
2.73
49
48
65
60
20.82
66.42
13.5
1.4
—
—
—
0
0
59
56
18.57
58.70
13.6
1.4
16.00
9.89
g/l
2.41
46
51
49
37
20.74
55.12
2.2
1.8
—
—
—
0
0
50
49
16.03
48.06
14.2
1.4
37.75
37.20
g/l
0.23
42
44
51
69
11.57
38.71
2.3
2.4
1.48
1.69
g/l
0.71
43
60
23
12
23.11
29.89
1.4
1.0
—
—
—
0
0
17
10
19.43
20.65
1.8
2.2
—
—
—
0
0
17
10
19.43
20.65
1.8
2.2
—
—
—
0
0
18
12
17.27
20.61
2.3
4.0
—
—
—
0
0
16
11
16.46
17.93
3.0
3.2
33.06
32.27
pg
0.24
16
11
22
32
8.08
14.93
1.9
1.5
—
—
—
0
0
105
571
5.51
14.76
17.2
6.6
1.22
1.21
mmol/l
1.28
84
482
51
169
4.34
14.14
3.4
2.4
23.15
22.31
%
0.13
46
153
19
25
8.74
13.95
1.2
1.2
—
—
—
0
0
54
192
4.12
13.51
2.6
1.9
—
—
—
0
0
17
22
8.75
12.60
2.1
1.5
—
—
—
0
0
19
32
6.79
11.22
1.9
1.5
—
—
—
0
0
16
9
20.05
11.04
1.9
1.6
—
—
—
0
0
15
7
24.00
10.97
1.5
2.4
—
—
—
0
0
65
294
3.44
10.89
3.0
2.0
2.80
3.14
mg/l
0.52
56
260
10
0
+∞
10.56
5.5
0.0
—
—
—
0
0
74
371
3.33
10.32
5.1
3.1
2.36
2.35
mmol/l
0.18
64
320
29
78
4.51
10.28
2.2
1.5
—
—
—
0
0
13
16
8.92
9.92
4.9
1.9
2.67
5.89
e9/l
3.21
13
16
13
17
8.39
9.45
6.3
3.3
52.31
67.35
%
1.76
13
17
13
19
7.50
8.61
2.3
1.3
—
—
—
0
0
37
135
3.44
8.45
2.8
1.9
—
—
—
0
0
13
20
7.12
8.23
2.1
1.6
—
—
—
0
0
18
39
5.20
8.16
2.7
2.6
—
—
—
0
0
37
138
3.36
8.13
2.8
2.0
—
—
—
0
0
11
14
8.50
8.11
1.2
1.8
—
—
—
0
0
14
24
6.42
8.04
2.0
1.5
—
—
—
0
0
11
15
7.92
7.67
1.2
1.7
—
—
—
0
0
59
302
2.76
7.29
2.2
1.5
19.99
19.83
nmol/l
0.03
49
252
11
16
7.42
7.27
2.2
1.6
—
—
—
0
0
10
13
8.25
7.22
2.6
1.2
—
—
—
0
0
10
14
7.66
6.80
1.3
1.9
—
—
—
0
0
10
14
7.66
6.80
1.3
1.9
—
—
—
0
0
10
14
7.66
6.80
1.3
1.9
—
—
—
0
0
14
30
5.11
6.38
1.9
1.2
—
—
—
0
0
71
420
2.54
6.29
4.8
3.5
—
—
—
0
0
11
20
5.92
5.91
2.2
1.6
—
—
—
0
0
51
271
2.46
5.54
2.0
1.7
1218.03
1219.21
nmol/l
0.00
38
207
75
476
2.38
5.43
2.9
2.0
91.27
90.98
pmol/l
0.02
43
242
10
18
5.94
5.41
1.7
1.3
—
—
—
0
0
9
10
9.57
4.87
1.3
1.2
—
—
—
0
0
8
9
9.38
4.34
1.4
1.8
14.75
11.67
u/l
—
8
9
55
330
2.16
4.29
5.0
3.3
1.01
0.40
e6/l
0.51
47
250
101
773
2.41
4.19
8.8
4.3
50.79
15.01
mm/h
12.87
96
699
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
37
3.80
4.17
5.7
1.9
0.26
0.38
u/ml
—
5
21
64
411
2.11
4.15
3.1
3.2
1043.97
1538.87
ng/l
1.04
57
346
8
10
8.44
4.12
4.9
2.6
—
—
—
0
0
72
486
2.09
4.07
7.0
4.4
—
—
—
0
0
7
7
10.48
4.06
1.3
1.9
—
—
—
0
0
7
7
10.48
4.06
1.3
1.9
—
—
—
0
0
7
7
10.48
4.06
1.3
1.9
—
—
—
0
0
7
7
10.48
4.06
1.3
1.9
—
—
—
0
0
6
5
12.49
3.80
1.5
1.8
11.20
33.16
u/l
—
6
5
6
5
12.49
3.80
1.0
2.0
—
—
—
0
0
41
229
2.16
3.76
2.5
1.6
3.27
1.59
mg/l
0.33
34
185
39
216
2.15
3.64
4.0
3.5
194.58
74.54
ng/l
0.37
33
190
19
76
2.76
3.57
2.4
1.8
—
—
—
0
0
6
6
10.40
3.53
1.5
1.3
—
—
—
0
0
44
262
2.03
3.37
3.8
2.6
—
—
—
0
0
6
7
8.91
3.30
1.3
1.7
—
—
—
0
0
6
7
8.91
3.30
1.3
1.7
—
—
—
0
0
6
7
8.91
3.30
2.8
1.1
—
—
—
0
0
6
7
8.91
3.30
2.8
1.1
—
—
—
0
0
22
99
2.47
3.29
15.4
4.2
1.26
1.22
mmol/l
1.66
22
83
27
134
2.28
3.26
1.2
1.3
0.80
22.93
u/ml
—
6
48
35
195
2.09
3.18
4.1
3.2
1.68
2.32
e6/l
0.26
22
110
29
151
2.19
3.12
1.3
1.3
30.89
40.94
iu/ml
—
7
51
6
8
7.79
3.09
1.3
1.6
—
—
—
0
0
11
35
3.34
3.01
1.6
1.5
—
—
—
0
0
35
200
2.03
2.96
3.7
3.0
2.66
1.04
e6/l
0.46
22
113
6
9
6.92
2.90
2.8
1.3
—
—
—
0
0
11
37
3.16
2.76
1.6
1.2
—
—
—
0
0
21
102
2.26
2.65
2.0
2.3
0.17
0.20
g/l
0.94
15
95
5
8
6.44
2.39
1.8
1.0
—
—
—
0
0
24
129
2.06
2.37
4.8
3.9
—
—
—
0
0
25
138
2.01
2.30
4.0
4.7
3.12
10.83
ug/l
1.48
19
112
6
13
4.78
2.30
1.2
1.1
—
—
—
0
0
7
18
4.05
2.28
1.9
1.2
—
—
—
0
0
63
464
1.70
2.28
3.0
2.3
—
—
—
0
0
7
19
3.83
2.18
1.7
1.5
—
—
—
0
0
11
43
2.70
2.16
2.3
1.9
—
—
—
0
0
5
10
5.15
2.09
4.0
1.1
—
—
—
0
0
18
91
2.14
2.07
2.1
3.0
33.31
29.94
u/l
0.15
13
77
6
15
4.14
2.06
1.3
1.2
—
—
—
0
0
16
79
2.17
1.95
1.8
1.4
—
—
—
0
0
5
12
4.29
1.84
1.4
1.2
—
—
—
0
0
15
76
2.10
1.72
6.7
5.9
24.87
24.70
mmol/l
0.09
15
76
86
722
1.57
1.61
3.4
3.9
15.11
15.09
pmol/l
0.02
74
632
6
20
3.09
1.60
1.2
1.2
—
—
—
0
0
0
44
0.00
1.54
0.0
1.8
—
—
—
0
0
7
27
2.68
1.54
1.7
1.4
—
—
—
0
0
6
21
2.94
1.52
2.2
1.4
—
—
—
0
0
6
21
2.94
1.52
2.2
1.4
—
—
—
0
0
5
16
3.21
1.45
3.8
3.6
—
—
—
0
0
17
104
1.73
1.16
9.8
7.0
1.26
1.19
mmol/l
0.20
17
97
92
812
1.46
1.13
47.1
18.8
34.08
38.36
%
2.94
58
502
17
105
1.71
1.13
2.2
1.9
316.94
381.32
nmol/l
0.77
17
96
13
79
1.72
0.92
4.1
4.1
5.14
5.11
kpa
0.05
13
73
88
789
1.36
0.86
57.4
21.7
14.53
13.94
%
2.56
88
773
87
951
0.74
0.82
4.9
6.8
37.55
41.44
mmol/mol
7.53
80
863
61
524
1.31
0.77
5.3
5.2
0.00
0.00
estimate
0.00
18
105
61
529
1.29
0.70
4.1
4.0
0.00
0.00
estimate
0.00
18
98
60
522
1.28
0.67
4.3
3.9
0.00
0.00
estimate
0.00
18
105
38
317
1.28
0.58
4.4
2.9
27.71
32.50
u/l
0.98
38
302
11
74
1.53
0.55
4.4
4.3
2.04
2.27
mmol/l
0.09
11
60
97
907
1.28
0.54
4.4
4.7
1.86
2.02
mu/l
0.53
88
794
6
39
1.56
0.54
2.5
1.7
—
—
—
0
0
86
921
0.80
0.52
3.2
4.5
1.06
1.25
mmol/l
3.06
74
819
56
499
1.22
0.47
4.2
4.3
48.43
55.76
ng/l
0.16
46
401
89
946
0.81
0.47
3.6
5.0
1.45
1.46
mmol/l
0.06
78
843
109
1041
1.30
0.45
47.8
21.3
83.83
83.95
umol/l
0.01
109
1041
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.9
—
—
—
0
0
22
264
0.80
0.38
1.4
1.9
538.65
459.12
pmol/l
0.42
17
218
53
482
1.17
0.34
3.9
5.5
2.35
2.93
ug/l
0.27
45
424
91
953
0.85
0.32
3.5
5.1
4.22
4.43
mmol/l
1.03
79
855
109
1054
1.22
0.30
42.9
20.5
139.13
139.58
mmol/l
1.15
109
1021
8
63
1.29
0.28
3.0
3.4
56.00
2385.98
u/ml
—
8
53
5
74
0.66
0.26
1.4
1.9
12.16
12.52
nmol/l
—
5
65
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
95
981
0.88
0.21
4.0
5.7
2.38
2.56
mmol/l
1.38
86
874
16
140
1.16
0.16
10.4
8.8
—
—
—
0
0
109
1069
1.13
0.14
62.9
25.9
119.86
133.20
g/l
13.21
109
1046
96
982
0.91
0.13
4.3
5.3
5.87
6.12
mmol/l
1.67
84
881
34
360
0.92
0.10
4.2
4.0
13.56
9.19
mg/mmol
0.29
23
227
32
304
1.07
0.08
5.2
4.2
0.00
0.00
estimate
0.00
16
97
9
87
1.04
0.07
1.1
1.3
—
—
—
0
0
95
935
1.06
0.07
42.8
17.0
75.02
72.77
ml/min/173m2
0.52
87
764
42
408
1.04
0.04
4.5
4.2
—
—
—
0
0
28
290
0.96
0.03
2.9
3.1
0.53
0.78
ug/l
2.72
21
204
10
104
0.96
0.00
1.5
1.2
—
—
—
0
0
14
143
0.98
0.00
3.6
5.2
40.75
31.57
%
—
8
84
38
384
0.99
0.00
3.7
4.7
21.10
20.47
%
0.11
23
195
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
15.06
—
0
5
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
7
70
1.00
0.00
5.9
3.7
0.88
0.15
e6/l
—
7
70
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_MACROGLOBULINEMIA – Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).